文献速递甲状腺核医学核素与放射性配体治疗

基因型指导MAPK抑制联合剂量学指导碘-131治疗恢复RAIR-DTC摄碘性

Restoring Radioiodine Avidity in Radioiodine-refractory Differentiated Thyroid Cancer With Genotype-guided MAPK Inhibition and Dosimetry-guided Radioiodine.
PubMed 文献 · Clin Nucl Med · 2026-02-04

这项单中心回顾性队列纳入11例放射性碘难治性分化型甲状腺癌(RAIR-DTC)患者,采用基因型导向的曲美替尼(±BRAF抑制)短程再分化后行剂量学指导的碘-131治疗;10/11例恢复摄碘(91%),10例接受碘-131者中8例(80%)达部分缓解,未发生≥3级不良事件。

要点

  • 短程基因型导向MAPK抑制可使多数RAIR-DTC恢复摄碘,支持作为碘-131治疗前的桥接策略。
  • 接受碘-131治疗者6个月影像显示部分缓解率80%,且再分化及后续RAI均未出现≥3级不良事件。
  • 部分患者可重复再分化联合碘-131周期并成功再诱导摄碘,提示个体化剂量学在现代管理中的价值。

核心结论

  • 短程基因型导向MAPK抑制可有效恢复RAIR-DTC摄碘性,并使剂量学指导的碘-131治疗安全可行。
  • 早期结构缓解常见、毒性轻微,部分患者可从重复再分化周期中获益。

研究设计与样本

  • 单中心回顾性队列纳入11例RAIR-DTC患者,接受基因型导向的曲美替尼(±BRAF抑制)再分化后行剂量学指导的碘-131治疗。
  • 再分化成功定义为再分化后诊断性123I SPECT/CT较基线碘摄取增加≥30%,或任一病灶活性≥2倍平均肝脏摄取。

主要发现

  • 11例中10例恢复摄碘(91%;精确95%CI 0.59-1.00)。
  • 2例接受第二轮再分化联合碘-131周期,均成功再诱导摄碘并获得持续疾病控制。
  • 接受碘-131治疗的10例中,6个月影像评估部分缓解8例(80%)、疾病稳定1例(10%)、进展1例(10%)。
  • 血清甲状腺球蛋白趋势与结构缓解总体一致,但3例因抗Tg干扰而解读受限。
  • 再分化及后续RAI期间未发生≥3级不良事件;中位随访39个月(IQR 20-54)。

关键数值与推荐

  • 再分化成功标准:再分化后诊断性123I SPECT/CT较基线碘摄取增加≥30%,或任一病灶活性≥2倍平均肝脏摄取。
  • 疗效评估采用RECIST 1.1,并以RAI前剂量学时间点为锚定以分离碘-131的治疗贡献。

临床怎么用

  • 对RAIR-DTC可考虑基因型导向的短程MAPK抑制作为再分化策略,并以个体化剂量学指导后续碘-131治疗。
  • 再分化成功后按剂量学结果实施碘-131治疗,并可在部分患者中评估重复再分化联合碘-131周期的获益。

局限性

  • 本研究为单中心回顾性队列,样本量仅11例。
  • 血清甲状腺球蛋白趋势解读受3例抗Tg干扰限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To evaluate the real-world effectiveness and safety of short-course MAPK pathway inhibition, integrated with individualized dosimetry, as a redifferentiation strategy in patients with radioiodine-refractory differentiated thyroid cancer (RAIR-DTC). PATIENTS AND METHODS: This retrospective single-center cohort included 11 patients with RAIR-DTC who underwent genotype-directed redifferentiation therapy with trametinib (±BRAF inhibition) followed by dosimetry-guided radioiodine therapy. Redifferentiation success was defined on post-redifferentiation diagnostic 123 I SPECT/CT as either a ≥30% increase in iodine uptake compared with baseline or any lesion demonstrating activity ≥2 times the mean hepatic uptake. RECIST 1.1 assessments were anchored to the pre-RAI dosimetry time point to isolate the therapeutic contribution of 131 I Clinical, biochemical, and imaging outcomes, including repeat redifferentiation cycles, were recorded. RESULTS: Restoration of iodine avidity occurred in 10 of 11 patients (91%; exact 95% CI, 0.59-1.00). Two patients underwent a second redifferentiation-plus-RAI cycle, both achieving successful reinduction of uptake and durable disease control. Among the 10 patients who received 131 I, partial response was observed in 8 (80%), stable disease in 1 (10%), and progression in 1 (10%) at 6-month imaging. Serum thyroglobulin trends were generally concordant with structural responses, although interpretation was limited by anti-Tg interference in 3 cases. No grade ≥3 adverse events occurred during redifferentiation or subsequent RAI. Median follow-up was 39 months (IQR: 20-54). CONCLUSIONS: Short-course, genotype-directed MAPK inhibition effectively restored iodine avidity and enabled safe, dosimetry-guided radioiodine therapy in a real-world RAIR-DTC cohort. Early structural responses were frequent, toxicity was minimal, and selected patients benefited from repeat redifferentiation cycles. These findings support the use of redifferentiation as a practical bridge to effective RAI and underscore the value of individualized dosimetry in modern RAIR-DTC management.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Demirkol MO, Kaya G, Seymen H, et al. Restoring Radioiodine Avidity in Radioiodine-refractory Differentiated Thyroid Cancer With Genotype-guided MAPK Inhibition and Dosimetry-guided Radioiodine. Clin Nucl Med. 2026. PMID: 41686811. doi:10.1097/RLU.0000000000006362

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。